ADBRY

• drugtralokinumab32 co-mentions · 8 sources
• tagApproval28 co-mentions · 7 sources
• companyLEO Pharma Inc20 co-mentions · 8 sources
• companyLeo Pharma AS14 co-mentions · 7 sources
• tagRecall2 co-mentions · 1 sources

Trials studying ADBRY

• phase2Tralokinumab Monotherapy for Children With Moderate-to-severe Atopic Dermatitis - TRAPEDS 1 (TRAlokinumab PEDiatric Trial no. 1)completedn=28
• phase1A Trial to Compare the Pharmacokinetics of Tralokinumab in Healthy Subjectscompletedn=101
• phase3A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitisrecruitingn=195
• —Intervention With Tralokinumab in Patients With Moderate-to-severe Atopic Dermatitis With Genital Impactrecruitingn=30
• phase3A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moderate-to-severe Atopic Hand Eczema Who Are Candidates for Systemic Therapycompletedn=235
• phase3Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 2 (ECZema TRAlokinumab Trial no. 2)completedn=794
• phase3Efficacy and Safety of Tralokinumab Administered by an Autoinjector in Adults and Adolescents With Moderate to Severe Atopic Dermatitis (INJECZTRA)completedn=136
• phase3Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3completedn=380